Prognostic Variables and Results of Salvage Treatment in Hodgkin's Disease

References

• Portlock C. S., Rosenberg S. A., Glatstein E. Impact of salvage treatment on initial relapses in patients with Hodgkin's disease stages I-III. Blood 1978; 51: 825–33
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr, Simon R. M., Hubbard S. M. Curability of advanced Hodgkin's disease with chemotherapy. Long-time follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587–95
   PubMed Web of Science ®Google Scholar
• Santoro A., Viviani S., Villarreal C. J. Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70: 343–8
   PubMedGoogle Scholar
• Bergsagel D. E. Salvage treatment of Hodgkin's disease in relapse. J Clin Oncol 1987; 5: 525–6
   PubMed Web of Science ®Google Scholar
• Roach M., Brophy R., Cox R. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623–9
   PubMed Web of Science ®Google Scholar
• Hoppe R. T. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A: 1920–2
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. The treatment of Hodgkin's disease. Ann Oncol 1994; 5(suppl 2)21–817
   Google Scholar
• Abrahamsen A. F., Hannisdal E., Nome O. Clinical stage I/II Hodgkin's disease; long-term results of therapy without laparotomy. Ann Oncol 1996; 7: 145–50
   PubMed Web of Science ®Google Scholar
• Fischer R. I., DeVita V. T., Hubbard S. P. Prolonged disease-free survival in Hodgkin's disease with MOPP-reinduction after first relapse. Ann Intern Med 1979; 90: 761–3
   PubMed Web of Science ®Google Scholar
• Canellos G. P. Is there an effective salvage therapy for advanced Hodgkin's disease?. Ann Oncol 1991; 2: 1–7
   PubMed Web of Science ®Google Scholar
• Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Sem Oncol 1990; 6: 716–35
   Google Scholar
• Canellos G. P. The second chance for advanced Hodgkin's disease. J Clin Oncol 1992; 10: 175–7
   PubMed Web of Science ®Google Scholar
• Longo D. L., Patricia L., Duffey R. C. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol 1992; 10: 210–8
   PubMed Web of Science ®Google Scholar
• Tubiana M., Attie E., Flamant R. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res 1971; 31: 1801–10
   PubMed Web of Science ®Google Scholar
• Hoppe R. T., Rosenberg S. A., Kaplan H. S. Prognostic factors in pathological stage IIIA Hodgkin's disease. Cancer 1980; 46: 1240–6
   PubMed Web of Science ®Google Scholar
• Mauch P., Tarbell N., Weinstein H. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 1576–83
   PubMed Web of Science ®Google Scholar
• Roach M, III, Brophy N., Cox R., Varghese A., Hoppe R. T. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623–9
   PubMed Web of Science ®Google Scholar
• Healey E. A., Tarbell N. J., Kalish L. A. Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 1993; 71: 2613–20
   PubMed Web of Science ®Google Scholar
• Proctor S. J., Taylor P., Donnan P. A numerical prognostic index for clinical use in identification of poor risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991; 27: 624–9
   PubMed Web of Science ®Google Scholar
• Haybittle J. L., Easterling M. J., Bennett M. H. Review of British national lymphoma investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1: 967–72
   PubMed Web of Science ®Google Scholar
• Proctor S. J., Taylor P., Mackie M. J. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Leukemia Lymphoma 1992; 7(suppl1)7–20
   Google Scholar
• Taylor P., Jackson G. H., Lennard A. L. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. Cancer 1993; 67: 683–7
   Web of Science ®Google Scholar
• Carbone PP, Kaplan H. S., Musshoff K. Reports of the committee on Hodgkin's disease staging. Cancer Res 1971; 31: 1960–1
   Google Scholar
• Sutcliffe S. B., Wrigley R. F., Peto J. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J 1978; 1: 679–84
   PubMed Web of Science ®Google Scholar
• McElwain T. J., Toy J., Smith E. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 1977; 36: 276–80
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Zucali R., Monfardini S. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 1975; 36: 252–9
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Bonfante V. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–5
   PubMed Web of Science ®Google Scholar
• Zittoun R, Eghbali H., Audebert A. Association d'epiru-bicine bleomycine vinblastine et prednisone (EBVP) avant radiotherapie dans les stades localises de la maladie de Hodgkin. Essai de phase II. Bull Cancer 1987; 74: 151–7
   PubMed Web of Science ®Google Scholar
• Dixon M. J., Brown M. B., Engelman L., Jennrich R. I. BMDP Statistical Software manual. University of California University Press, Berkeley 1990
   Google Scholar
• Peto R., Pike M. C., Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation for each patient. II Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Early bone marrow transplantation in Hodgkin's disease. Ann Oncol 1994; 5(Suppl. 2)3–161
   PubMed Web of Science ®Google Scholar